Literature DB >> 2123886

Enhancement of anti-influenza A virus cytotoxicity following influenza A virus vaccination in older, chronically ill adults.

G J Gorse1, R B Belshe.   

Abstract

We studied anti-influenza cytotoxicity by bulk peripheral blood mononuclear leukocyte (PBL) cultures derived from older, chronically ill volunteers undergoing vaccination. Vaccinees received either cold-recombinant, live-attenuated influenza A/Korea/1/82 (H3N2) virus intranasally or inactivated monovalent influenza A/Taiwan/1/86 (H1N1) subvirion vaccine intramuscularly. PBL were collected pre- and postvaccination and in vitro stimulated by autologous PBL infected with influenza A virus homologous and heterosubtypic to the respective vaccine strain. Cytotoxicity was measured against influenza A virus-infected autologous and human leukocyte antigen (HLA)-mismatched PBL targets infected with influenza A virus homologous or heterosubtypic to the vaccine virus strain. Vaccinees infected with the live-attenuated virus developed significant rises in mean anti-influenza, HLA-restricted cytotoxicity that was cross-reactive against influenza A viruses homologous and heterosubtypic to the vaccine virus. The enhanced cross-reactive cytotoxicity was inducible postvaccination by in vitro stimulation with autologous PBL infected with the homologous influenza A (H3N2) virus and with influenza A (H1N1) virus. In contrast, after vaccination with inactivated monovalent subvirion vaccine, volunteers developed significant increases in mean anti-influenza, HLA-restricted cytotoxicity only against autologous PBL infected with homologous influenza A (H1N1) virus. Increased cytotoxicity occurred only after in vitro stimulation with autologous cells infected with homologous influenza A (H1N1) virus. Mean gamma interferon levels in supernatant fluids of influenza A virus-stimulated effector PBL did not increase postvaccination, despite increased levels of anti-influenza cytotoxicity displayed by the effector cells. We conclude that the live-attenuated influenza A virus infection induced a broader range of enhanced anti-influenza cytotoxicity than did the inactivated subvirion vaccine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123886      PMCID: PMC268221          DOI: 10.1128/jcm.28.11.2539-2550.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Cell-mediated cytotoxicity following influenza infection and vaccination in humans.

Authors:  R C Reichman; V G Pons; B R Murphy; E A Caplan; R Dolin
Journal:  J Med Virol       Date:  1979       Impact factor: 2.327

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Influenza virus-specific cytotoxic T cells in man; induction and properties of the cytotoxic cell.

Authors:  A J McMichael; B A Askonas
Journal:  Eur J Immunol       Date:  1978-10       Impact factor: 5.532

4.  The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes.

Authors:  K L Yap; G L Ada
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

5.  Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents.

Authors:  M A Phelan; R E Mayner; D J Bucher; F A Ennis
Journal:  J Biol Stand       Date:  1980

6.  Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25 degrees between recent H3N2 and H1N1 epidemic strains and cold-adapted A/An Arbor/6/60.

Authors:  N J Cox; H F Maassab; A P Kendal
Journal:  Virology       Date:  1979-08       Impact factor: 3.616

7.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

8.  Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation.

Authors:  S B Greenberg; H R Six; S Drake; R B Couch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

9.  Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice.

Authors:  R G Webster; B A Askonas
Journal:  Eur J Immunol       Date:  1980-05       Impact factor: 5.532

10.  Virus specificity of human influenza virus-immune cytotoxic T cells.

Authors:  W E Biddison; S Shaw; D L Nelson
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

View more
  20 in total

1.  Repeated influenza vaccination of healthy children and adults: borrow now, pay later?

Authors:  F Carrat; A Lavenu; S Cauchemez; S Deleger
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

2.  Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Authors:  I Mbawuike; Y Zang; R B Couch
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

3.  Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.

Authors:  Bin Zhou; Yan Li; Scott D Speer; Anju Subba; Xudong Lin; David E Wentworth
Journal:  Vaccine       Date:  2012-03-24       Impact factor: 3.641

4.  Progress toward the development of universal influenza vaccines.

Authors:  Daniel F Hoft; Robert B Belshe
Journal:  Mo Med       Date:  2014 Jul-Aug

Review 5.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

6.  Attenuated influenza virus construct with enhanced hemagglutinin protein expression.

Authors:  Jad Maamary; Natalie Pica; Alan Belicha-Villanueva; Yi-ying Chou; Florian Krammer; Qinshan Gao; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

7.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

8.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01

9.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

10.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Authors:  Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.